We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Early into their hotly anticipated migraine launches, Amgen and Eli Lilly have picked up key coverage from Express Scripts, but Teva's Ajovy was left out in the cold.